Latest News
Annovis Bio, Inc.
- Annovis Bio, Inc. Estimates – NYSE:ANVS
- Annovis Bio to Present Buntanetap Data at CTAD as Phase 3 Readout Nears
- Annovis to Attend the CTAD 2026 with Three Presentations
- AI research will predict which potential Alzheimer’s treatments reach the brain. It’s one of three Annovis presentations.
- Annovis Bio Updates Audit Fee Details in June 2026 Proxy Statement Correction
- Annovis Bio corrects 2025 audit fees to $415,000, total fees $515,000
- Annovis turns to AI to fast-track its Alzheimer’s filing
- Annovis Bio, AI platform partner to support drug application
Headlines from the last 30 days, linking to the original publishers. See all market news →